the following definitions are provided for some of the terms used throughout this specification . as used herein , “ normal lp ( a ) concentration ” refers to an average plasma lp ( a ) concentration below 25 mg / dl . as used herein , “ elevated lp ( a ) concentration ” refers to an average plasma lp ( a ) concentration above 25 mg / dl . as used herein , “ acute elevation of lp ( a ) concentration ” refers to an average plasma lp ( a ) concentration above 25 mg / dl less than the course of a week . as used herein , “ chronic elevated lp ( a ) concentration ” refers to an average plasma lp ( a ) concentration above 25 mg / dl more than the course of a week . as used herein , “ total - cholesterol ” refers to a summation of cholesterol in plasma that are contained in the major plasma lipoproteins such as chylomicrons , vldl , ldl and hdl . as used herein , “ ldl - cholesterol ” refers to cholesterol contained in plasma ldl lipoprotein . as used herein , “ cardiovascular diseases ”, in the context of the present invention , refers to those disease states associated with high levels of lp ( a ) in plasma as well as other lipoproteins such as ldl ; and includes , inter alia , arteriosclerosis , atherosclerosis , coronary artery disease , peripheral artery disease , myocardial infarction , stroke , restenosis and bypass graft stenosis . as used herein , the term “ an effective amount ” used herein refers to that an amount of the biochemical composition disclosed in this application , when administered to a human subject in need thereof , is sufficient to lower plasma lp ( a ) concentration or inhibit the generation of apo ( a ), or reduce plasma concentrations of other lipoproteins . as used herein , the term “ therapeutically effective amount ” used herein refers to an amount of biochemical composition disclosed in this application , which when administered to a human subject in need thereof , is sufficient to effect treatment for disease states alleviated by the reduction of lp ( a ) or other lipoproteins . the therapeutically effective amounts can be determined routinely by one of ordinary skill in the art having regard to his / her knowledge and tho this disclosure . as used herein , the term “ treatment ” refers to treating a disease state in human , which disease state is alleviated by the reduction of plasma levels of lp ( a ) or other lipoproteins ; and include inhibition the disease or relieving the disease . “ treatment ” used herein also includes preventing , inhibiting or relieving the disease state from occurring in a human . as used herein , the term “ pharmaceutically acceptable salt ” refers to those salts which retain the biological effectiveness and properties of the active ingredient of the biochemical composition , which are not otherwise undesirable . pharmaceutically acceptable salts include , but not limited to , the sodium , potassium , calcium , magnesium , aluminum and the like . as used herein , the term “ ascorbate ” include any pharmaceutically acceptable salt of ascorbate , including sodium ascorbate , as well as ascorbic acid itself . the term “ lysine ” refers to lysine in its electrically neutral form or a pharmaceutically acceptable salt of lysine which includes lysine hydrochloride , lysine dihydrochloride , lysine succinate , lysine glutamate , and lysine orotate . the term “ proline ” refers to proline and proline in a pharmaceutical acceptable salt of proline which includes proline hydrochloride , proline glutamate and the like . an increased concentration of plasma lp ( a ) represents a risk factor for stroke and cardiac infarction . since lp ( a ) in plasma is exclusively produced in the liver , we concluded that the primary cause of an overproduction of lp ( a ) should be an impaired metabolism in liver cells ( hepatocytes ). the cause of this metabolic impairment would be a deficiency of certain biochemical compounds needed as coenzymes in the krebs - cycle , the respiration chain and for other metabolic functions in hepatocytes . the krebs cycle is also called the tricarboxylic acid ( tca ) cycle and the citric acid cycle . it is the final common catabolic pathway for the oxidation of fuel molecules . two carbons enter the citric acid cycle as acetyl coa and two carbons leave as co 2 . in the course of the cycle , four oxidation - reduction reactions take place to yield reduction potential in the form of three molecules of nadh and one molecule of fadh 2 . a high energy phosphate bond ( gtp ) is also formed . additional embodiments and advantages of the invention will be set forth in the description that follows , and in part will be obvious from the description , or may be learned by practice of the invention . this invention may be realized and obtained by means of the composition and method of treatment particularly pointed out from the description and drawings , and from the claims . a composition of biochemical substances can contain at least one ascorbate compound selected from the group consisting of ascorbic acid , pharmaceutically acceptable ascorbate salts and / or mixtures thereof in combination with at least one niacin compound selected from the group of nicotinic acid , niacin amide or another niacin salt , lysine hydrochloride , or pharmaceutically acceptable lysine salts , proline hydrochloride or pharmaceutically acceptable salts thereof and / or mixtures of these compounds . the composition can be effective to lower plasma levels of lipoprotein ( a ), low - density lipoprotein ( ldl ), cholesterol , triglycerides , homocysteine and / or other metabolic risk factors for cardiovascular disease . examples of pharmaceutical compositions useful for the prevention or treatment of cardiovascular disease are described , for example , in u . s . pat . nos . 5 , 278 , 189 , 5 , 650 , 418 , 5 , 230 , 996 , each of which is incorporated herein in its entirety . administration of the compounds of the invention , in pure form or in an appropriate pharmaceutical composition , can be carried out via any of the acceptable modes of administration or pharmaceutically acceptable means of delivery that may serve similar utilities . the modes of administration and pharmaceutically acceptable means of delivery include , but not limited to , oral , nasal , parenteral , topical or transdermal administration or delivery in the form of solid , semi - solid , lyophilized powder , or liquid dosage forms . the dosage forms include tablets , suppositories , pills , soft elastic and hard gelatin capsules , powders , solutions , suspensions , or aerosols , or the like , preferably in unit dosage forms suitable for simple administration of precise dosages . the compositions may include a conventional pharmaceutical carrier or excipient and a compound of the invention as the active agent , and in addition , may include other medicinal agents , pharmaceutical agents , carriers , adjuvants , etc . the preferred route of administration is oral , using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease state to be treated . for such oral administration , a pharmaceutically acceptable composition containing the compounds of the invention , or a pharmaceutically acceptable salt thereof , is formed by the incorporation of any of the normally employed , pharmaceutically acceptable excipients , such as , pharmaceutical grades of mannitol , lactose , starch , pregelatinized starch , magnesium stearate , sodium saccharine , talcum , cellulose ether derivatives , glucose gelatin , sucrose , citrate , propyl gallate , and the like . such compositions take the form of solutions , suspensions , tablets , pills , capsules , powders , sustained release formulations and the like . preferably such compositions will take the form of capsule , caplet , or tablet and therefore will also contain a diluent such as lactose , sucrose dicalcium phosphate , and the like ; a disintegrant such as croscarmellose sodium or derivatives thereof ; a lubricant such as magnesium stearate and the like ; and a binder such as a starch , gum acacia , polyvinylpyrrolidone , gelatin , cellulose ether derivatives , and the like . the compounds of the invention in pharmaceutically acceptable form are administrated in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compounds employed ; the metabolic stability and length of action of the compounds ; the age , body weight , general health , sex and diet of the patient ; the mode and time of administration ; the rate of excretion ; the drug combination ; the severity of the particular disease states ; and the patient undergoing treatment . generally , a therapeutically effective daily dose is not less than about 10 % and not more than about 200 % of the amounts of individual ingredients listed in table 1 . most preferably , a therapeutically effective daily dose is about 50 % identical with the list of components in table 1 . the following specific examples are provided as a guide to assist in the practice of the invention , and are not intended as a limitation on the scope of the invention . this example illustrates the preparation of a representative pharmaceutical composition containing the biochemical compounds listed in the following table ( table 1 ). to demonstrate the utility of the composition of the invention as therapeutic agents for treating disease states which are alleviated by the reduction of plasma lp ( a ) levels , we evaluated the composition of these biochemical compounds for its ability to lowering plasma lp ( a ) and other lipoproteins in humans . we administered the biochemical composition containing the compounds listed in table 1 in a prospective clinical study with 14 patients . various clinical parameters were recorded before the administration of the composition . blood samples were collected via venipuncture at the beginning of the study and plasma levels of various lipoproteins were monitored with elisa assays . the ages of this group of 14 patients ranged from 34 to 68 years old . this group of human subjects were clinically classified as polygenic hyperlipidemia . the average plasma level of lp ( a ) was 71 mg / dl . the average plasma total cholesterol level was 293 mg / dl . the average plasma ldl - cholesterol level was 195 mg / dl . the average plasma triglyceride level was 193 mg / dl . these patients received the biochemical compounds listed in table 1 as a daily dosage . the patients received the compounds of the invention for a period of three months . at the end of the three months after the therapeutic intervention , blood samples were again collected via venipuncture at the end of the study . plasma concentrations of various lipoproteins were monitored with elisa assays . results of the study , as illustrated in fig1 and fig2 demonstrates that the patents , after therapeutic administration of compositions , had led to the following average decrease in plasma levels of . 1 . lp ( a ) from 71 mg / dl to 64 mg / dl , a decrease of 13 %; 2 . total - cholesterol from 293 mg / dl to 252 mg / dl , a decrease of 14 %; 3 . ldl - cholesterol from 195 mg / dl to 176 mg / dl , a decrease of 10 %; and 4 . triglycerides from 193 mg / dl to 151 mg / dl , a decrease of 22 %. the results are further depicted graphically in fig1 and fig2 . [ 0060 ] fig1 is a graph for a pilot study conducted with 14 patients with various forms of lipid disorders ( hyperlipoproteinemia ). their average lipoprotein ( a ) levels at study entry were 71 mg / dl ( milligrams per deciliter ). after therapeutic use of the formula of table 1 the lipoprotein ( a ) levels were lowered within 12 weeks to an average of 62 mg / dl . this equals a reduction in the plasma concentration of this risk factor by 13 %. [ 0061 ] fig2 is a graph showing the lowering effect of the composition of table 1 on additional risk factors for cardiovascular diseases . within 12 weeks of therapy the total cholesterol levels decreased on average from 293 mg / dl to 252 mg / dl (- 14 %), the ldl - cholesterol from 195 mg / dl to 16 mg / dl (− 10 %) and triglycerides from 193 mg / dl to 151 mg / dl (− 22 %). when the chemical compounds of the present invention are combined , the concentration of plasma lipoproteins is significantly reduced . this combined effect is surprising in its effectiveness in lowering the plasma concentration of these lipoproteins as well as the risk of cardiovascular diseases . the lowering of the plasma concentration over the duration of 12 weeks indicates the therapeutic potential of the biochemical composition in controlling chronic elevation of lipoproteins in humans . while the present invention has been described with reference to the specific embodiments thereof , it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention . one of the ordinary skill in the art would appreciate that the effective amounts of the biochemical compounds may vary depending on the variations in patients , durations of treatment etc . modifications may be made to adapt a particular situation , and composition of matter . a number of embodiments of the invention have been described in the present application ; nevertheless , it will be understood all such modifications are intended to be within the scope of the following claims .
the present invention provides compositions and methods for lowering plasma lp levels in humans . the present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases . moreover , this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol , ldl - cholesterol , triglycerides and other metabolic risk factors .